Who is this for?
This is for men with advanced prostate cancer (mCRPC) — and especially for those whose cancer is found to carry a mutation in a DNA-repair gene, such as BRCA1, BRCA2, or another HRR gene.
About 1 in 4 men with advanced prostate cancer have one of these DNA-repair mutations in their tumor, and about 1 in 8 to 1 in 10 have a BRCA mutation specifically. These men make up a distinct group: their cancer tends to behave more aggressively — but it also has a built-in weakness that PARP-inhibitor drugs are designed to exploit.
What kind of evidence is this?
This is a review that pulls together the three large phase III trials that combined a PARP inhibitor with hormone therapy in advanced prostate cancer — PROpel, TALAPRO-2, and MAGNITUDE — together with a 2025 expert analysis (published in a Lancet journal) of how those trials should be interpreted, and which men truly benefit.
Background: an Achilles’ heel in the cancer’s DNA
Every cell constantly repairs damage to its DNA, using several different repair systems as backups for one another. Two of them matter here: the HRR system (which includes the BRCA genes) and an enzyme called PARP.
Some prostate cancers carry a mutation that breaks the HRR system. Those cancer cells survive by leaning heavily on their other repair route — PARP. That creates an opening. If you give a drug that blocks PARP, a cancer cell that has already lost its HRR repair is left with no way to fix its DNA, and it dies. A healthy cell, with its HRR system intact, simply switches back to it and survives. Scientists call this two-hit trap “synthetic lethality.”
The evidence: what was tested
PARP inhibitors are used in prostate cancer in two ways:
- On their own, for men whose cancer has a DNA-repair mutation and has already progressed after a hormone pill. Two trials (PROfound with olaparib, TRITON3 with rucaparib) showed this slows the cancer in mutation-carriers.
- Combined with a hormone pill, earlier, as a first treatment for mCRPC. This is where the three big recent trials come in — and where the important question lies: does adding a PARP inhibitor help everyone, or only men with a mutation?
The three combination trials were built differently, which turns out to matter a great deal:
- MAGNITUDE (niraparib + abiraterone) enrolled men selected for a DNA-repair mutation, and separately tested men without one — so it could tell the two groups apart.
- TALAPRO-2 (talazoparib + enzalutamide) and PROpel (olaparib + abiraterone) enrolled all comers, mutation or not, and looked at the whole group together.
The main measure in each was how long the cancer was held back on scans (radiographic progression-free survival).
Results: the benefit depends on the mutation
Read together, the trials tell a consistent story: the clearer the DNA-repair mutation, the clearer the benefit — and where there is no mutation, the benefit largely disappears.
Adding a PARP inhibitor to hormone therapy — time until the cancer grew on scans
The time the cancer was controlled was nearly doubled — a 45% lower risk of progression or death (HR 0.55). This is the group that benefits most.
Across the whole group the combination also delayed progression (HR 0.63) — but much of that benefit is driven by the mutation-carriers within the group, which makes the number for men without a mutation harder to pin down.
When men without a mutation were studied on their own, adding the PARP inhibitor did not help — that part of the trial was stopped early for futility. This is the crux of the debate.
This is exactly why the 2025 review argues that the mutation should guide the decision. Regulators have drawn the line in different places — the US FDA generally restricts these combinations to men with a BRCA (or broader HRR) mutation, while Europe’s EMA approved some of them for all men — but the biology points the same way: the treatment is built to exploit a specific weakness, and it works best when that weakness is present.
What is “synthetic lethality,” in one line?
It means two changes that are each survivable on their own become lethal when combined. A cancer cell can survive losing its BRCA repair (it leans on PARP), and a normal cell can survive a PARP-blocking drug (it leans on BRCA). But a cancer cell that has both knocked out — BRCA by mutation, PARP by the drug — can no longer fix its DNA and dies. The drug is lethal specifically to the mutated cancer cells.
Should I have genetic testing?
If you have advanced prostate cancer, testing for DNA-repair mutations is now standard, because it directly affects treatment options. There are two kinds: tumor testing (of a biopsy, looking at the cancer’s own genes) and germline testing (a blood or saliva test for inherited mutations). Both matter. Germline BRCA results also have implications for blood relatives, so genetic counseling is usually offered. Ask your oncologist whether you have been tested and what was found.
Are there side effects?
Yes. The most common problem with PARP inhibitors is anemia (low red blood cells), which can cause fatigue and sometimes needs a dose reduction or transfusion; low platelets and nausea also occur. Blood counts are monitored closely. When combined with a hormone pill, the side effects of both are added together, which is part of why matching the treatment to the men most likely to benefit is so important.
The bottom line
PARP inhibitors are a genuinely new, targeted way to treat advanced prostate cancer — but they are not for everyone equally. Their benefit is greatest and clearest in men whose cancer carries a BRCA mutation (where they nearly doubled the time the cancer was controlled), meaningful across the broader group of DNA-repair (HRR) mutations, and largely absent in men with no such mutation. The single most useful step for a man with advanced prostate cancer is therefore genetic testing — it reveals whether this treatment is likely to help.
What this could mean for you
- Ask about genetic testing. Both tumor and inherited (germline) testing for BRCA and other HRR mutations are now standard in advanced prostate cancer — they open up (or rule out) this option.
- If you carry a mutation, a PARP inhibitor — alone or combined with a hormone pill — may be one of your most effective options.
- If you don’t, the benefit is much less certain, and the added side effects may not be worth it — a conversation worth having honestly with your oncologist.
- Family matters too. An inherited BRCA result can affect blood relatives, so genetic counseling is usually part of the process.
Questions & comments
Have a question about this research? Ask below. Questions are read and answered by the site. We can’t give personal medical advice, but we’re glad to explain the research more clearly.